We would like to thank everyone who visited our booth, took a look at our posters or took part in our tutorials and making the inaugural SLAS 2012 in San Diego great success for BMG LABTECH.
Most attendees were enthralled with the new Gold-Standard for High-throughput Screening (HTS), the PHERAstar FS, while others were attracted to the new Atmospheric Control Unit (ACU), cell-based assay screening accessory for the Omega series of microplate readers.
If you missed us at the show, you can still obtain a PDF copy of our tutorial presentations or posters by visiting http://www.bmglabtech.com/sbs.
- Automated HTS Platform Tailored for NanoLiter Volumes - The Ability to Go Smaller.
As 1536-well plates were introduced to high throughput screening (HTS), adoption was not immediate. Now instruments with 1536-well capability are a mandatory consideration for most HTS workflows. Will the pattern stay true for screening in 3456-well formats? In this tutorial, BMG LABTECH and Labcyte present a new platform incorporating next generation instrumentation and software for nanoliter-scale HTS. See how this fully automated nanoHTS platform can screen more compounds faster while lowering your average screening costs
- New HTS Tools for Discovering Low Affinity Inhibitors in Primary and Secondary Screens
Analysis of high-throughput screening data has shown two trends, classic HTS platforms have not delivered the number of expected drug leads as once thought and the more promising lead compounds have low molecular weights (<500 Da). Since classic HTS platforms are performed at low volumes and low concentrations, are the more marketable lower affinity drug targets being missed with older, less sensitive platforms? In this tutorial learn how when using the IP-One HTRF® assay from Cisbio, lower affinity hits were found on the next generation PHERAstar FS microplate reader but were completely missed on a leading CCD based reader. Being more than twice as fast and having far superior assay quality parameters (Z prime, delta F% and assay window), the PHERAstar FS represents a new choice for finding low affinity compounds in this and other HTS screening paradigms.
- Nano High-Throughput Screening (nHTS) Platform - Miniaturization of Cell-based GPCR and Kinase Assays
Over the last decade it has become apparent that classic high-throughput screening (HTS) platforms have not yielded the number of marketable drugs as once thought they would. Furthermore, analysis has shown that most drugs that do go to market tend to have low molecular weights (<500 Da). This suggests that classic HTS screens, which are performed at lower volumes and lower concentrations, seem to be missing the more marketable lower affinity drug targets. As a consequence different or new technologies, such as NMR, are being used to detect lower affinity compounds or compound fragments. This type of screening has issues as well, though, and there is still considerable interest in using classic HTS bioassays to look for low affinity compounds.
Using the the IP-One HTRF® assay from Cisbio, which measures the lower response second messenger inositol 1,4,5-triphosphate (IP3), two different HTS microplate readers with different detection technologies were assessed. A next-generation photomultiplier (PMT) based instrument was compared to an industry leading high-performance charged coupled device (CCD) based camera imaging instrument. The data here shows that the PMT reader clearly outperformes the CCD reader, being more than twice as fast and having superior assay quality parameters (Z prime, dF% and assay window). More importantly, it revealed several lower affinity drug ‘hits’ that were not found by the CCD based reader. This next-generation HTS reader, the PHERAstar FS from BMG LABTECH, represents a new choice for finding low affinity compounds in this and other classic HTS screening paradigms.
- Next-Generation HTS Instrument Discovers Low Affinity Inhibitors of the Inositol Phosphate (IP) Signaling Pathway
Traditional ELISA assays are known for their several wash steps in order to remove unbound antigen from the well. Here we introduce a fluorescence based ELISA assay that only needs one wash step. This technology is called ELISAONE™ and was developed by TGR BioSciences. The ELISAONE™ assay is both robust and sensitive as evidenced by EGF, TNFa and IL-2 data obtained with the POLARstar Omega microplate reader from BMG LABTECH
- Validation of Transcreener® Fluorescent Polarization Assays using The BMG LABTECH`S PHERAstar PlusTranscreener® assays from BellBrook Labs offers generic, universal HTS assays for nucleotide detection like ADP, UDP, GDP and AMP. These assays are available in three detection modes-Fluorescent Polarization (FP); Fluorescent Intensity (FI) and Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET). The PHERAstar series of microplate readers is perfect for all three detection formats especially FP and TR-FRET. It uses a unique Simultaneous Dual Emission detection system that measures both emission wavelengths in one read of the microplate. Simultaneous Dual Emission detection not only reduces plate read times by half, it corrects for any signal variations due to differences in well volumes, concentrations, or fluctuations in excitation energy. In this poster we show the performance of PHERAstar PLUS for detection of different nucleotides in the Transcreener® FP assay. The instrument can achieve a Z`>0.6 at 10% conversion for all the Transcreener assays tested with a ∆mP greater than 100 at 10% conversion.